Search Result

Pathways Recommended:	Antibody-drug Conjugate/ADC Related

Results for "

CEACAM5 antibody

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibody (2) Antibody-Drug Conjugates (ADCs) (3) Microtubule/Tubulin (1) Radionuclide-Drug Conjugates (RDCs) (1) Topoisomerase (1) Transmembrane Glycoprotein (9)
By Research Areas:	Cancer (10) Inflammation/Immunology (3)

Inhibitors & Agonists

Fluorescent Dyes

Inhibitory Antibodies

Antibodies

Targets Recommended: ADC Antibody Antibody-Drug Conjugates (ADCs) Antibody-Oligonucleotide Conjugates (AOCs) ADC Linker PROTAC-Linker Conjugates for PAC

Cat. No.	상품명	Target	연구분야	Chemical Structure

HY-P99054

Tusamitamab SAR-408377; PF-08046050 antibody; SAR445953 antibody	Transmembrane Glycoprotein ADC Antibody	Cancer
Tusamitamab is an IgG1 monoclonal antibody that targets *CEACAM5*. Tusamitamab can be used to synthesize ADC Tusamitamab ravtansine (SAR408701) (HY-P99542) .

HY-P99542

Tusamitamab ravtansine SAR-408701; HuMAb2-3-SPDB-DM4	Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin	Cancer
Tusamitamab ravtansine (SAR-408701) is a targeted ADC against tumor cells expressing *CEACAM5, composed of a humanized anti-CEACAM5* monoclonal antibody covalently linked to the potent cytotoxic agent, maytansinoid DM4 (HY-12454), via a cleavable linker. Tusamitamab ravtansine has an average drug-to-antibody ratio (DAR) of 3.8 .

HY-177434

Precemtabart tocentecan Precem-TcT; M 9140	Antibody-Drug Conjugates (ADCs) Transmembrane Glycoprotein Topoisomerase	Cancer
Precemtabart tocentecan (Precem-TcT; M 9140) is an anti-CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5) antibody-drug conjugate (ADC). Precemtabart tocentecan consists of a tumor-specific anti-CEACAM5 monoclonal antibody Precemtabart (HY-P990940), a highly hydrophilic and stable cleavable β-glucuronide linker, and a topoisomerase 1 inhibitor payload Exatecan (HY-13631), and the drug-linker conjugate for ADC is Mal-Gly-PAB-Exatecan-D-glucuronic acid (HY-153179). Precemtabart tocentecan inhibits the growth of CEACAM5-positive cancer cells. Precemtabart tocentecan exhibits significant antitumor activity in CEACAM5-expressing xenograft models. Precemtabart tocentecan can be used for the study of CEACAM5-expressing advanced solid tumors, especially mCRC .

HY-P99681

Labetuzumab govitecan IMMU 130; hMN-14-SN-38	Antibody-Drug Conjugates (ADCs)	Cancer
Labetuzumab govitecan (IMMU 130) is an Anti-CEACAM5/SN-38 antibody-drug conjugate (ADC). Labetuzumab govitecan consists of the antibody Labetuzumab, SN-38, and a pH-sensitive Linker. Labetuzumab govitecan can be used for research of cancers, such as colorectal cancer .

HY-P991060

Cergutuzumab	Transmembrane Glycoprotein	Cancer
Cergutuzumab is a fully human IgG1 antibody that targets carcinoembryonic antigen (CEA, *CEACAM5, CD66e*). Cergutuzumab can be used to form the recombinant protein Cergutuzumab amunaleukin (HY-P99498) .

HY-P991469

AMG-211 MEDI-565	Transmembrane Glycoprotein	Cancer
AMG-211 (MEDI-565)i s a bispecific antibody targeting CD3E and *CEACAM5/CEA/CD66e*. AMG-211 can be used in Gastrointestinal cancer and Solid tumours research .

HY-P990853

Anti-CEACAM5 Antibody (4H11-8)	Transmembrane Glycoprotein	Cancer
Anti-CEACAM5 Antibody (4H11-8) is a kind of mouse IgG1 κ chimeric antibody, targeting to human *CEACAM5. Anti-CEACAM5* Antibody (4H11-8) reacts with human CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5). Anti-CEACAM5 Antibody (4H11-8) can be used for detecting CEACAM5 in cancer.

HY-P991936

Anti-CEACAM5/CEA/CD66e Antibody (16C3)	Transmembrane Glycoprotein	Cancer
Anti-CEACAM5/CEA/CD66e Antibody (16C3) is an antibody against human *CEACAM5/CEA/CD66e*. Recommend Isotype Controls:?Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P992090

Altumomab	Radionuclide-Drug Conjugates (RDCs) Transmembrane Glycoprotein	Inflammation/Immunology
Altumomab is a anti-huamn monoclonal antibody targeting *CEACAM5/CEA/CD66e* .

HY-P992350

EBC-129 Antibody	ADC Antibody Transmembrane Glycoprotein	Cancer
EBC-129 Antibody is a specific antibody for the synthetic antibody-drug conjugate (ADC) EBC-129, which specifically targets *CEACAM5* and *CEACAM6* glycosylated at N256. EBC-129 Antibody can be used for the research of pancreatic ductal adenocarcinoma .

HY-P992344

DNP002	Transmembrane Glycoprotein	Cancer
DNP002 is a humanized IgG1 monoclonal antibody targeting tumor-associated *CEACAM6. DNP002 binds to CEACAM1, CEACAM5* and *CEACAM6, and exhibits antibody-dependent cellular cytotoxicity against tumor cells overexpressing these targets. DNP002 binds to CEACAM6* on the surface of tumor-associated neutrophils (including MDSCs) to reverse the immunosuppressive effect in the tumor microenvironment. DNP002 shows anti-tumor activity in advanced solid tumors. DNP002 can be used for the research of advanced solid tumors. The recommended isotype control is human IgG1 kappa (HY-P99001) .

Cat. No.	상품명	Type

HY-177434

Precemtabart tocentecan Precem-TcT; M 9140	Fluorescent Dyes
Precemtabart tocentecan (Precem-TcT; M 9140) is an anti-CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5) antibody-drug conjugate (ADC). Precemtabart tocentecan consists of a tumor-specific anti-CEACAM5 monoclonal antibody Precemtabart (HY-P990940), a highly hydrophilic and stable cleavable β-glucuronide linker, and a topoisomerase 1 inhibitor payload Exatecan (HY-13631), and the drug-linker conjugate for ADC is Mal-Gly-PAB-Exatecan-D-glucuronic acid (HY-153179). Precemtabart tocentecan inhibits the growth of CEACAM5-positive cancer cells. Precemtabart tocentecan exhibits significant antitumor activity in CEACAM5-expressing xenograft models. Precemtabart tocentecan can be used for the study of CEACAM5-expressing advanced solid tumors, especially mCRC .

Precemtabart tocentecan

Precem-TcT; M 9140

Fluorescent Dyes

Precemtabart tocentecan (Precem-TcT; M 9140) is an anti-CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5) antibody-drug conjugate (ADC). Precemtabart tocentecan consists of a tumor-specific anti-CEACAM5 monoclonal antibody Precemtabart (HY-P990940), a highly hydrophilic and stable cleavable β-glucuronide linker, and a topoisomerase 1 inhibitor payload Exatecan (HY-13631), and the drug-linker conjugate for ADC is Mal-Gly-PAB-Exatecan-D-glucuronic acid (HY-153179). Precemtabart tocentecan inhibits the growth of CEACAM5-positive cancer cells. Precemtabart tocentecan exhibits significant antitumor activity in CEACAM5-expressing xenograft models. Precemtabart tocentecan can be used for the study of CEACAM5-expressing advanced solid tumors, especially mCRC .

Cat. No.	상품명	Target	Research Area	Image

HY-P99054

Tusamitamab SAR-408377; PF-08046050 antibody; SAR445953 antibody	Transmembrane Glycoprotein ADC Antibody	Cancer
Tusamitamab is an IgG1 monoclonal antibody that targets *CEACAM5*. Tusamitamab can be used to synthesize ADC Tusamitamab ravtansine (SAR408701) (HY-P99542) .

HY-P99542

Tusamitamab ravtansine SAR-408701; HuMAb2-3-SPDB-DM4	Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin	Cancer
Tusamitamab ravtansine (SAR-408701) is a targeted ADC against tumor cells expressing *CEACAM5, composed of a humanized anti-CEACAM5* monoclonal antibody covalently linked to the potent cytotoxic agent, maytansinoid DM4 (HY-12454), via a cleavable linker. Tusamitamab ravtansine has an average drug-to-antibody ratio (DAR) of 3.8 .

HY-P990940

Precemtabart MBE-748; M-9140 antibody; MBE-2882 antibody	Inhibitory Antibodies	Inflammation/Immunology
HY-P990940 is an *CEACAM5*-targeting IgG1κ type human antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P991060

Cergutuzumab	Transmembrane Glycoprotein	Cancer
Cergutuzumab is a fully human IgG1 antibody that targets carcinoembryonic antigen (CEA, *CEACAM5, CD66e*). Cergutuzumab can be used to form the recombinant protein Cergutuzumab amunaleukin (HY-P99498) .

HY-P991563

Anti-CEACAM5 Antibody (A5B7)	Inhibitory Antibodies	Others
Anti-CEACAM5 Antibody (A5B7) is a humanized antibody expressed in CHO cells, targeting *CEACAM5/CEA/CD66e. Anti-CEACAM5* Antibody (A5B7) consists of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-CEACAM5 Antibody (A5B7) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P991469

AMG-211 MEDI-565	Transmembrane Glycoprotein	Cancer
AMG-211 (MEDI-565)i s a bispecific antibody targeting CD3E and *CEACAM5/CEA/CD66e*. AMG-211 can be used in Gastrointestinal cancer and Solid tumours research .

HY-P990853

Anti-CEACAM5 Antibody (4H11-8)	Transmembrane Glycoprotein	Cancer
Anti-CEACAM5 Antibody (4H11-8) is a kind of mouse IgG1 κ chimeric antibody, targeting to human *CEACAM5. Anti-CEACAM5* Antibody (4H11-8) reacts with human CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5). Anti-CEACAM5 Antibody (4H11-8) can be used for detecting CEACAM5 in cancer.

HY-P990365

**Anti-CEACAM5/CEA/CD66e Antibody**	Inhibitory Antibodies	Inflammation/Immunology
The Anti-CEACAM5/CEA/CD66e Antibody is a humanized antibody expressed in CHO cells, targeting *CEACAM5/CEA/CD66e. The Anti-CEACAM5/CEA/CD66e Antibody* has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-CEACAM5/CEA/CD66e Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P991936

Anti-CEACAM5/CEA/CD66e Antibody (16C3)	Transmembrane Glycoprotein	Cancer
Anti-CEACAM5/CEA/CD66e Antibody (16C3) is an antibody against human *CEACAM5/CEA/CD66e*. Recommend Isotype Controls:?Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P992090

Altumomab	Radionuclide-Drug Conjugates (RDCs) Transmembrane Glycoprotein	Inflammation/Immunology
Altumomab is a anti-huamn monoclonal antibody targeting *CEACAM5/CEA/CD66e* .

HY-P992350

EBC-129 Antibody	ADC Antibody Transmembrane Glycoprotein	Cancer
EBC-129 Antibody is a specific antibody for the synthetic antibody-drug conjugate (ADC) EBC-129, which specifically targets *CEACAM5* and *CEACAM6* glycosylated at N256. EBC-129 Antibody can be used for the research of pancreatic ductal adenocarcinoma .

HY-P992344

DNP002	Transmembrane Glycoprotein	Cancer
DNP002 is a humanized IgG1 monoclonal antibody targeting tumor-associated *CEACAM6. DNP002 binds to CEACAM1, CEACAM5* and *CEACAM6, and exhibits antibody-dependent cellular cytotoxicity against tumor cells overexpressing these targets. DNP002 binds to CEACAM6* on the surface of tumor-associated neutrophils (including MDSCs) to reverse the immunosuppressive effect in the tumor microenvironment. DNP002 shows anti-tumor activity in advanced solid tumors. DNP002 can be used for the research of advanced solid tumors. The recommended isotype control is human IgG1 kappa (HY-P99001) .

Host:	Mouse (4) Rabbit (1)
Reactivity:	Human (5)
Application:	IHC-P (5) ICC/IF (1) IF-Tissue (2) IHC-F (2) WB (3) ELISA (2)
Isotype:	IgG (2) IgG1 (2)
Conjugation:	Non-conjugated (5)
Clonality:	Monoclonal (2) Monoclonal Antibody (1) Recombinant (1)
Modification:	Unmodified (3)

Cat. No.	Compare	상품명	Application	Reactivity	Image

HY-P83977

	CEA Antibody (YA3674) CEA; CD66e; DKFZp781M2392; CEACAM5	IHC-P, ELISA	Human
	CEA Antibody (YA3674) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CEA.

HY-P83977A

	CEA Antibody (YA3674)(PBS only) CEA; CD66e; DKFZp781M2392; CEACAM5	IHC-P, ELISA	Human
	CEA Antibody (YA3674) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CEA.

HY-P85091

	CEA Antibody (YA4783) CEACAM5; CEA; Carcinoembryonic antigen-related cell adhesion molecule 5; Carcinoembryonic antigen; CEA; Meconium antigen 100; CD antigen CD66e	WB, IHC-P, IHC-F, IF-Tissue	Human
	CEA Antibody (YA4783) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to CEA.

HY-P85091A

	CEA Antibody (YA4783)(PBS only) CEACAM5; CEA; Carcinoembryonic antigen-related cell adhesion molecule 5; Carcinoembryonic antigen; CEA; Meconium antigen 100; CD antigen CD66e	WB, IHC-P, IHC-F, IF-Tissue	Human
	CEA Antibody (YA4783) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to CEA.

HY-P81080

	CEA Antibody (YA917) Carcinoembryonic antigen; Carcinoembryonic antigen related cell adhesion molecule 5; Carcinoembryonic antigen-related cell adhesion molecule 5; CD66e; CD66e antigen; CEACAM5; CEAM5_HUMAN; DKFZp781M2392; Meconium antigen 100.	WB, IHC-P, ICC/IF	Human
	CEA Antibody (YA917) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CEA.

Compare Products


Products	해외재고보유 - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / 해외재고보유 - + 장바구니에 담기 견적 받기

온라인 문의

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
호칭			Country or Region *
고객명 *			회사명 *
Department *
메일주소 *			상품명 *
Cat. No.			Requested quantity *
전화번호 *
비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent:

Name
이메일 *

	Sorry, but the email address you supplied was invalid.